fda semaglutide shortage resolved feb 21 2025 Announces FDA ends semaglutide shortage, closing

$90 for a 4-week supply senior pricing No membership or subscription fees

The current generation of GLP-1 receptor agonists includes: Semaglutide (weekly subcutaneous injection or oral formulation) Liraglutide (daily subcutaneous injection) Tirzepatide (dual GLP-1/GIP receptor agonist, weekly subcutaneous injection) Each of these GLP-1 agents carries a distinct pharmacological profile, and the optimal choice depends on a patients clinical history, metabolic risk factors, and therapeutic goals a determination best made in consultation with a physician experienced in metabolic and longevity medicine

What happens if you do not rotate retatrutide injection sites

Stimulant laxatives, such as Dulcolax, senna/sennosides, and Senokot (Bisacodyl)

(See Figure M) Figure M Step 15

But the FDA is clear: localized supply chain lag does not constitute a national shortage